We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front-line all-trans retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high-dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gentuzumab ozogamicin (MylotargTM CMA-676) / Petti, Mc; Pinazzi, Mb; Diverio, D; Romano, A; Petrucci, Mt; DE SANTIS, S; Meloni, Giovanna; Tafuri, Agostino; Mandelli, Franco. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 115:1(2001), pp. 63-65. [10.1046/j.1365-2141.2001.03091.x]

Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gentuzumab ozogamicin (MylotargTM CMA-676).

MELONI, Giovanna;TAFURI, Agostino;MANDELLI, Franco
2001

Abstract

We report a patient with acute promyelocytic leukaemia (APL) who received two doses of gemtuzumab ozogamicin for advanced disease. Previous treatments included front-line all-trans retinoic acid and anthracyclines, polychemotherapy consolidation, salvage chemotherapy for the first relapse followed by autologous stem cell transplantation (ASCT), arsenic trioxide for the second relapse followed by a second ASCT and then high-dose methotrexate for more advanced systemic disease with central nervous system involvement. The patient achieved prolonged haematological and molecular remission after monotherapy with gemtuzumab ozogamicin given at the time of the third relapse.
2001
gemtuzumab ozogamicin; acute promyelocytic leukaemia; PML; RARα; molecular remission; CD33
01 Pubblicazione su rivista::01a Articolo in rivista
Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gentuzumab ozogamicin (MylotargTM CMA-676) / Petti, Mc; Pinazzi, Mb; Diverio, D; Romano, A; Petrucci, Mt; DE SANTIS, S; Meloni, Giovanna; Tafuri, Agostino; Mandelli, Franco. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - 115:1(2001), pp. 63-65. [10.1046/j.1365-2141.2001.03091.x]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/255962
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 67
  • ???jsp.display-item.citation.isi??? 47
social impact